UNSPSC 51334301: Chlorprothixene

This classification denotes an antipsychotic agent with the molecular formula C18H18ClNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9S7OD60EWP, chemically known as 3-(2-chlorothioxanthen-9-ylidene)-n,n-dimethyl-propan-1-amine but generally known as chlorprothixene, which bears US NIH Compound Identifier 2729. European Medicines Agency schedules Chlorprothixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06210MIG.

UNSPSC 51334301 Chlorprothixene is a Commodity code nominally identifying a specific antipsychotic medication, but recent state and local solicitations tagged under this code do not reflect purchases of chlorprothixene itself. Instead, the three most recent opportunities show state and local governments procuring naloxone and drug deactivation systems, therapeutic pharmacy initiatives involving direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The actual buying activity under this code encompasses pharmaceutical procurement more broadly—from emergency response medications like naloxone to generic drug supply agreements managed through state and regional cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances; Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration's Office of State Procurement are recent buyers. The code shows limited specificity in recent practice, suggesting either broad tagging of pharmaceutical purchases or misalignment between the code's nominal scope and how jurisdictions are actually classifying their pharmaceutical procurement activity.

Geographic activity centers on Florida, Texas, and Minnesota based on the three most recent opportunities. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) closing July 26, 2023 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission released an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent and administrative fee and compliance factors at 25 percent combined. The code shows minimal activity that clearly aligns with chlorprothixene procurement specifically.